NASDAQ:ATHA Athira Pharma (ATHA) Stock Price, News & Analysis $0.63 +0.02 (+3.98%) (As of 12:37 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Athira Pharma Stock (NASDAQ:ATHA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Athira Pharma alerts:Sign Up Key Stats Today's Range$0.57▼$0.6750-Day Range$0.42▼$3.3052-Week Range$0.41▼$4.30Volume6.31 million shsAverage Volume1.63 million shsMarket Capitalization$24.22 millionP/E RatioN/ADividend YieldN/APrice Target$13.83Consensus RatingHold Company OverviewAthira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Read More… CRUSHED: How Biden's Replacement Will Devastate Your 401(k)! (Ad)Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << Athira Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks55th Percentile Overall ScoreATHA MarketRank™: Athira Pharma scored higher than 55% of companies evaluated by MarketBeat, and ranked 518th out of 972 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingAthira Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAthira Pharma has only been the subject of 4 research reports in the past 90 days.Read more about Athira Pharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Athira Pharma are expected to grow in the coming year, from ($2.57) to ($1.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Athira Pharma is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athira Pharma is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAthira Pharma has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Athira Pharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.41% of the float of Athira Pharma has been sold short.Short Interest Ratio / Days to CoverAthira Pharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Athira Pharma has recently decreased by 0.64%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAthira Pharma does not currently pay a dividend.Dividend GrowthAthira Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.41% of the float of Athira Pharma has been sold short.Short Interest Ratio / Days to CoverAthira Pharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Athira Pharma has recently decreased by 0.64%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Athira Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ATHA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Athira Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,033.00 in company stock.Percentage Held by Insiders19.80% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Athira Pharma's insider trading history. Receive ATHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ATHA Stock News HeadlinesAthira Pharma (NASDAQ:ATHA) Stock Quotes, Forecast and News SummaryNovember 3 at 3:34 PM | benzinga.comAthira Pharma to present results from Phase 2/3 LIFT-AD trialOctober 22, 2024 | markets.businessinsider.comRigged election? Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late. November 4, 2024 | Porter & Company (Ad)Athira Pharma files $300M mixed securities shelfOctober 22, 2024 | markets.businessinsider.comMizuho Downgrades Athira Pharma (ATHA)September 20, 2024 | msn.comHold Rating on Athira Pharma Amid Strategic Pivot and Clinical UncertaintySeptember 18, 2024 | markets.businessinsider.comAthira Pharma to Cut About 70% of WorkforceSeptember 17, 2024 | marketwatch.comAthira Pharma: A Cautious Hold Amid Strategic Pivot and Clinical ProgressSeptember 17, 2024 | markets.businessinsider.comSee More Headlines ATHA Stock Analysis - Frequently Asked Questions How have ATHA shares performed this year? Athira Pharma's stock was trading at $2.43 on January 1st, 2024. Since then, ATHA stock has decreased by 74.3% and is now trading at $0.6250. View the best growth stocks for 2024 here. How were Athira Pharma's earnings last quarter? Athira Pharma, Inc. (NASDAQ:ATHA) posted its quarterly earnings data on Thursday, August, 1st. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.05. When did Athira Pharma IPO? Athira Pharma (ATHA) raised $160 million in an initial public offering on Friday, September 18th 2020. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel served as the underwriters for the IPO and JMP Securities was co-manager. Who are Athira Pharma's major shareholders? Athira Pharma's top institutional investors include Bristlecone Advisors LLC (0.88%). Insiders that own company stock include Perceptive Advisors Llc, Glenna Mileson, Mark James Litton, Andrew Gengos, Kelly A Romano, Hans Moebius, Mark Worthington, Rachel Lenington and James A Johnson. View institutional ownership trends. How do I buy shares of Athira Pharma? Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Athira Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Athira Pharma investors own include Palantir Technologies (PLTR), Pfizer (PFE), PayPal (PYPL), Advanced Micro Devices (AMD), Alibaba Group (BABA), Intel (INTC) and Meta Platforms (META). Company Calendar Last Earnings8/01/2024Today11/04/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATHA CUSIPN/A CIK1620463 Webathira.com Phone425-620-8501FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$13.83 High Stock Price Target$22.00 Low Stock Price Target$0.50 Potential Upside/Downside+2,113.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-95.53% Return on Assets-76.96% Debt Debt-to-Equity RatioN/A Current Ratio3.97 Quick Ratio3.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book0.18Miscellaneous Outstanding Shares38,440,000Free Float30,828,000Market Cap$24.03 million OptionableOptionable Beta2.82 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:ATHA) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.